⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 21, 2024PharmaceuticalsOpen Access

Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022

Marwan Alrasheed Khalid A. Alamer Mashael Albishi Abdulrahman Alsuhibani Omar A. Almohammed Abdulrahman Alwhaibi Abdullah N. Almajed Jeff J. Guo

View Full Paper

Ask AI

Bookmark

Share

Abstract

New multiple myeloma (MM) medications have revolutionized the treatment landscape, but they are also associated with a range of adverse events (AEs). This study aims to provide a comprehensive overview of AEs reported for four new MM medications: daratumumab, ixazomib, elotuzumab, and panobinostat.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alrasheed et al. (2024) studied this question.

synapsesocial.com/papers/68e63d09b6db6435875ceaff https://doi.org/10.3390/ph17070815

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System2024 · 2 citations
2Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System2024 · 1 citations
3Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study2024 · 3 citations
4Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS2024 · 6 citations
5Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting systemOriginal Research · 2025